CUSIP 55287L101COMMBXQ4 2025
22 filings · latest Feb 11, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 6.65M | $209.80M |
| 2 | Orbimed Advisors LLC | 3.94M | $124.12M |
| 3 | Nea Management Company, LLC | 3.61M | $114.00M |
| 4 | Wellington Management Group LLP | 3.35M | $105.66M |
| 5 | Deep Track Capital, LP | 3.25M | $102.50M |
| 6 | Blackrock, Inc. | 2.92M | $92.09M |
| 7 | Nvp Associates, LLC | 2.14M | $67.38M |
| 8 | Ecor1 Capital, LLC | 2.12M | $66.98M |
| 9 |
| 4 | Nov 14, 2025 | P. Kent Hawryluk | 13G/A | 4.3% | 2.00M | SEC |
| 5 | Nov 12, 2025 | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 13G/A | 4.5% | 2.02M | SEC |
| 6 | Nov 10, 2025 | New Enterprise Associates 17, L.P. | 13D/A | 8.1% | — | SEC |
| 7 | Oct 6, 2025 | Wellington Management Group LLP | 13G/A | 10.8% | 4.82M | SEC |
| 8 | Sep 30, 2025 | Norwest Venture Partners Xvi, LP | 13D/A | 4.8% | — | SEC |
| 9 | Sep 30, 2025 | Frazier Life Sciences Public Fund, L.P. | 13D/A | 11.7% | — | SEC |
| 10 | Sep 30, 2025 | Orbimed Advisors LLC | 13D/A | 9.0% | — | SEC |
See the full Schedule 13D/13G history for Mbx Biosciences Inc.
Unlock full history| Vanguard Group Inc |
| 1.82M |
| $57.33M |
| 10 | Driehaus Capital Management LLC | 1.41M | $44.41M |